SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 17.07 |
| Book Value / Share | n/a |
| Price / Book | n/a |
| NCAV ($M) | 2.58 |
| NCAV / Share | n/a |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.63 |
| Return on Assets (ROA) | -0.28 |
| Return on Equity (ROE) | -0.37 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.30 |
| Current Ratio | 3.30 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 8.43 |
| Assets | 22.92 |
| Liabilities | 5.85 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -17.80 |
| Net Income | -15.49 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -14.68 |
| Cash from Investing | 0.00 |
| Cash from Financing | 15.11 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Apeiron Investment Group Ltd. |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 69,271 | 253,550 | 27.32 | |
| 35,763 | 231,507 | 15.45 | |
| 150,729 | 663,732 | 22.71 | |
| 7,514,523 | 25,136,628 | 29.89 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MURA – Mural Oncology plc | NAII – Natural Alternatives International, Inc. |
| NAMS – NewAmsterdam Pharma Company N.V. | NGNE – Neurogene Inc. |
| NKGN – NKGen Biotech, Inc. |
Financial data and stock pages provided by
Fintel.io